The Foundation for the National Institutes of Health Names Recipients of the 2024 Charles A. Sanders, MD, Partnership Award
June 18 2024 - 8:17AM
Business Wire
The Foundation for the National Institutes of Health (FNIH) will
award the 2024 Charles A. Sanders, MD, Partnership Award to the
National Institutes of Health’s (NIH) National Institute of
Neurological Disorders and Stroke (NINDS), AbbVie, and Robert and
Sarah Newcomb. The Partnership Award recognizes persons or
organizations that have made significant contributions to the
FNIH’s work in support of the mission of the NIH.
“We are grateful to work with these outstanding partners and
celebrate their many contributions to our research programs,” said
FNIH President and CEO Julie Gerberding, MD, MPH. “Their dedication
to advancing medical breakthroughs and their commitment to
excellence underpin our success.”
NINDS, one of the NIH’s 27 Institutes and Centers, has partnered
with the FNIH on a diverse range of public-private projects. NINDS
is the NIH lead for the recently launched Accelerating Medicines
Partnership® (AMP®) for Amyotrophic Lateral Sclerosis, AMP
Parkinson’s Disease, and the Neurofilament as a Fluid Biomarker of
Neurodegeneration in Familial Frontotemporal Degeneration project.
NINDS supports future and early-career doctors and scholars with
its participation in the Congress of Neurological Surgeons
Foundation’s Getch Scholars program for neurosurgeons and its
partnership in a summer internship program for undergraduate,
graduate, and medical students. Additionally, the FNIH works with
NINDS on endowments focused on funding research for muscular
dystrophy and multiple sclerosis and supporting an annual
lecture.
For the past 13 years, AbbVie has participated in more than 20
FNIH-managed projects across a broad range of therapeutic areas. As
a longstanding partner of the FNIH Biomarkers Consortium, AbbVie
has helped accelerate and advance discovery and development for
biomarkers that support new drug therapeutics, preventive medicine
and diagnostics in areas such as osteoarthritis, multiple myeloma
and acute myeloid leukemia. AbbVie also has been a partner in
several AMP programs, including those focused on Parkinson’s
disease, Alzheimer’s disease, and rheumatoid arthritis and systemic
lupus erythematous. Additionally, the company has participated in
the Convening Experts in Oncology to Address Children’s Health
(COACH) project, which seeks to advance therapeutic developments in
childhood cancers, and the Lung Cancer Master Protocol (Lung-MAP),
a precision medicine trial in non-small cell lung cancer.
Robert and Sarah Newcomb are longstanding partners of the FNIH.
In 2001, they established a memorial fund to honor their late son,
Robert Whitney Newcomb, PhD, and further his work on brain research
and the chemical basis of stroke and aging at NINDS. Dr. Newcomb
began research at NIH when in high school and continued later with
a postdoctoral NIH grant. The Robert Whitney Newcomb Memorial Fund
has provided substantial support in training and educational
opportunities at the Institute. This contribution has funded 21
annual lectures on neurobiology and 27 high school internships in
the laboratory of Susan Wray PhD, of the Cellular and Developmental
Biology Section, and post-baccalaureate fellowships. Family,
friends and colleagues of Dr. Newcomb have generously contributed
to the Fund, with the commitment to continue supporting educational
opportunities at NINDS.
The Charles A. Sanders, MD, Partnership Award is named for the
former Chairman of the FNIH Board of Directors. The recipients will
be awarded at the 12th Annual FNIH Awards Ceremony on the evening
of October 29, 2024, in Washington, D.C. The FNIH 2024 Lurie Prize
in Biomedical Sciences and the 2024 Trailblazer Prize for
Clinician-Scientists also will be presented during the Awards
Ceremony.
The FNIH gratefully acknowledges its Annual Awards Ceremony
Premier Sponsors, Fred and Donna Seigel, and our Visionary
Sponsors, Paul and Sandra Montrone, Dr. Gilbert S. Omenn and Ms.
Martha A. Darling, and Steven and Jann Paul, MD.
For more information about the Partnership Award, click
here.
About the Foundation for the National Institutes of
Health
The Foundation for the National Institutes of Health (FNIH)
builds public-private partnerships that connect leading biomedical
scientists at the National Institutes of Health (NIH) with their
counterparts in life sciences companies, academia, patient
organizations, foundations, and regulatory agencies (including the
Food and Drug Administration and European Medicines Agency).
Through team science, the FNIH solves complex health challenges and
accelerates breakthroughs for patients, regardless of who they are
or what health threats they face. The FNIH contributes to the
development of new therapies, diagnostics, and potential cures;
advances global health and equity in care; and celebrates and helps
train the next generations of scientists. Established by Congress
in 1990 to support the mission of the NIH, the FNIH is a
not-for-profit 501(c)(3) charitable organization. For more
information about the FNIH, please visit fnih.org.
Follow us on social media: LinkedIn, X, Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240617847911/en/
Kathy Scarbeck FNIH 301-827-6648 kscarbeck@fnih.org